Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 15/20 | 0.58 |
| ▸ | RAB9A | P51151 | 14/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820140 | 0.78 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL1544104 | 0.75 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL22854566 | 0.75 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL2459287 | 0.75 | NPC1 (0.79) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL28958633 | 0.74 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL6979614 | 0.74 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL10162052 | 0.74 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL4811437 | 0.74 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL2432415 | 0.74 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL15810252 | 0.72 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | claimed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | claimed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION | 2005-11-03 | — | — | US | disclosed |
| EP-1494663-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SmithKline Beecham Corporation (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086385-A1 | DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245596-A1 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss | CTSK, CTSB, CTSD | NPC1 1181/4885RAB9A 1430/4885SMN1; SMN2 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.